昭衍新藥(603127.SH):實控人之一馮宇霞質押延期484萬股
格隆匯 10 月 23日丨昭衍新藥(603127.SH)公佈,馮宇霞因個人資金需要,於2020年10月22日申請將該部分已質押到期的484萬股進行延期,延期購回日為2020年12月3日。馮宇霞個人資信狀況良好,具備相應的資金償還能力,累計質押的股份不存在平倉風險。本次延期質押不會導致公司實際控制權發生變更。在質押期內,若出現相關業務風險,馮宇霞將積極採取補充質押、提前還款、提前購回被質押股份等相應措施應對風險。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.